All News

Robert A. Figlin, MD, highlights toxicities that patients with renal cell carcinoma experience while on cabozantinib.

At the end of 2020, investigators saw more patients being screened for cancer compared with the beginning of the year, although racial and economic disparities still exist for certain tests.

The FDA has requested a partial clinical hold on all trials featuring melflufen following the updated results of the phase 3 OCEAN study in relapsed/refractory multiple myeloma.

The FDA released a final guidance on evaluating cancer drugs in patients with central nervous system metastases.

Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.

The FDA supported Athenex to continue developing oral paclitaxel and encequidar for patients with metastatic breast cancer.

The pharmaceutical company plans to voluntarily withdraw the accelerated approval indication for pembrolizumab in the third line setting for patients with gastric cancer within the coming months.

A dose-escalation schedule for neratinib may help some patients with HER2-positive breast cancer better manage severe diarrhea resulting from treatment.

In a trial of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and other hematologic cancers, the BCL-2 inhibitor lisaftoclax demonstrated feasibility as a treated option in the relapsed or refractory setting.

Patients with KRAS-positive NSCLC being treated with rigosertib plus nivolumab demonstrated early efficacy of the combination in a phase 1/2a trial.

Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.

CancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.

FoundationOne CDx, a comprehensive genomic profiling test, has been approved for use in conjunction with brigatinib to test for solid tumors in patients with ALK-positive NSCLC.

Pembrolizumab has been granted an expanded indication by the FDA for locally advanced cutaneous squamous cell carcinoma.

Patients with Wilms Tumor-1–positive ovarian cancer have shown promising response to the combination of galinpepimut-s and pembrolizumab.

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

Catch up on the important updates from CancerNetwork® last week you might have missed in the world of oncology.

Based on its potential to prolong overall survival in patients with glioblastoma multiforme, berubicin was granted fast track designation for the FDA for the treatment of recurrent disease.

Agha emphasized that the annual conference allows investigators to set the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

Final overall survival results from TOURMALINE-MM1 failed to show statistical significance of an ixazomib combination for relapsed/refractory multiple myeloma overall.

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

Stephanie White, DO, and Preeti Kotha, PharmD, detailed their experiences running the WesternU Health Clinic COVID-19 vaccine program from when vaccines were first approved in the United States until now.

New findings indicate that historically underserved patient populations with renal cell carcinoma are more likely to receive non–guidance-based treatment.

Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.

Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.

Ibrutinib and venetoclax may prove beneficial in previously untreated chronic lymphocytic leukemia.

Patients who discontinued endocrine therapy early were more likely to have experienced significant mental, physical, and social adverse effects of treatment.

Phase 2 data showed just over half of patients given dual therapy had a major pathological response, compared to just 6.7% of those receiving durvalumab monotherapy.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, to discuss recent updates in the treatment of gastrointestinal malignancies.

CancerNetwork® sat down with Salma Jabbour, MD, of Rutgers Cancer Institute, at 2021 ASCO to talk about what she believed was the most interesting and impactful study to come out of the meeting.